Navigation Links
Mild Asthma, a Revolutionary Therapy from Italian Research

Published by the New England Journal of Medicine the B.E.S.T study conducted in Italy

“TAKEN ONLY WHEN NEEDED AND THE DISEASE CAN BE CONTROLLED SUCCESSFULLY”

Prof. Fabbri: “Daily drug useless for mild persistent types affecting over one million 200 thousand people”. Chiesi’s commitment to pneumological research

MILAN, Italy, 29th May 2007 – Farewell to the daily dose of cortisone necessary for the control of mild persistent asthma: an Italian study has demonstrated that successful management of the disease is possible in the early stages without the need for daily maintenance therapy. A new “when needed” approach that may significantly improve the quality of life for one million 200 thousand Italians suffering from this disease. Amongst these sufferers there are also those suffering from allergic asthma, which is very common particularly at this time of year.

These are the results of a clinical study on BEST (BEclomethasone plus Salbutamol Treatment), published by the New England Journal of Medicine, one of the most prestigious international medical publications, sponsored by Chiesi Farmaceutici and the most important pneumological centres in Italy. “This is a revolutionary study – says research coordinator, Professor Leonardo Fabbri, Head of the Clinic for Respiratory Tract Diseases at the University of Modena and Reggio Emilia – as it questions a pivotal issue within the therapeutic programme for asthma in this group of patients. Our research has demonstrated that basic inhalant therapy with a preconstituted combination of a bronchodilator (salbutamol) and cortisone (beclometasone dipropionate), taken when symptoms first appear, allows clinical control similar to that provided by continuous daily inhalant therapy with cortisone plus bronchodilator when required, as recommended by current guidelines. Clinical research in Italy gains important international recogni
'"/>




Page: 1 2 3

Related medicine technology :

1. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
2. Revolutionary Immunologic Data Explains Function of Diamyd Diabetes Vaccine
3. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
4. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
7. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
8. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
9. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
10. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
11. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Mild Asthma Revolutionary Therapy from Italian Research
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
(Date:8/19/2014)...  The Alabama Supreme Court, in a 6-3 decision on ... who mislead doctors into believing that prescription medicines the companies ... v. Wyeth, and the decision came after the Supreme Court ... year. Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a ...
(Date:8/19/2014)... , Aug. 19, 2014  Northwest Biotherapeutics (NASDAQ: ... DCVax® personalized immune therapies for solid tumor cancers, announced ... last Thursday, August 14, 2014, has closed.  The three-year ... at $7.30 per share of common stock.  The investors ... purchase up to an additional 30% of these notes ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3
... Epiphany Biosciences announced,today, the initiation of a ... treatment and management of acute infectious,mononucleosis. Currently, there ... debilitating condition or any other disease caused by,the ... broad spectrum of anti-viral activity,including inhibition of viral ...
... SAN FRANCISCO, Calif., Dec. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... (NYSE: PFE ), has begun a Phase 1 ... syk kinase inhibitor, R343,for the treatment of allergic asthma. ... Under the terms of the companies, 2005 collaboration ...
Cached Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
(Date:8/20/2014)... Santa Rosa, CA (PRWEB) August 20, 2014 ... is the 12 per diode panel band perfect spectrum that ... plants are most likely to use during photosynthesis. A ... spectral bands is that they almost exclusively reside between 440-480 ... 620-680 on the red side of the spectrum. The KIND ...
(Date:8/20/2014)... 2014 Get the report here: ... presents “Deal Drivers 2014 Half Year Report for the ... activity in both North and South America, with targeted ... Merrill DataSite     , Merrill DataSite is a secure ... due diligence process by providing a highly efficient and ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Understanding ... governmental and physician stakeholders networks impacting the launch ... America, US, Canada, and Emerging Markets. , This ... Experts’ perspectives on stakeholder management needs for the ... immunotherapy and targeted therapy investigational agents that are ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 ... it is bringing on Wrench Advisors as a ... tasks including international large accounts. , As Wrench ... sales consultants can help your organization plan and ... executives and global distribution channels. Our experience developing ...
(Date:8/20/2014)... Beach, Florida (PRWEB) August 20, 2014 ... Florida, with the help of their experienced surgeons trained ... of patients to regain their lost or inaccurate vision. ... for performing Lasik surgery is making it possible for ... aging disease which occurs normally in people in the ...
Breaking Medicine News(10 mins):Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2Health News:Register to Download Merrill DataSite's Report: Deal Drivers 2014 Half Year Report for the Americas 2Health News:Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting 2Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:Braverman Eye Center Now Offers Multifocal PresbyLasik in Florida by Trained Surgeons 2
... August 2, 2009 The world,s top lung cancer ... in San Francisco, CA for the 13th World Conference ... for the Study of Lung Cancer (IASLC). Prevention and ... lung cancer remains one of the hardest cancers to ...
... , , , ... around the world are turning to cosmetic surgery in increasing numbers, ... "moobs" ("man boobs".) , , Male cosmetic surgery ... countries where the stigma attached to male cosmetic surgery has all ...
... , MINNEAPOLIS, July 28 Employees ... boots this week as the cooperative put in place a new ... to execute a voluntary recall of instant nonfat dried milk, whey ... new protocols for the dry ingredients production area in preparation for ...
... cell lung cancer (NSCLC) patients over the age of ... erlotinib, Fox Chase Cancer Center researchers reported today at ... Study of Lung Cancer. "Based on our initial ... efficacious, though we,ll have to wait and see the ...
... 1, 2009 The world,s top lung cancer specialists, ... San Francisco, CA for the 13th World Conference on ... the Study of Lung Cancer (IASLC). According to a ... therapies, as first-line treatment, have the potential to slow ...
... ... its entry into the interventional radiology marketplace with the nationwide launch of its new ... ... entry into the interventional radiology marketplace with the nationwide launch of its new ...
Cached Medicine News:Health News:Diagnostic tools and innovative therapies improve patient prognosis 2Health News:Diagnostic tools and innovative therapies improve patient prognosis 3Health News:Diagnostic tools and innovative therapies improve patient prognosis 4Health News:Diagnostic tools and innovative therapies improve patient prognosis 5Health News:Diagnostic tools and innovative therapies improve patient prognosis 6Health News:Men Around the World Seek Cosmetic Surgery 2Health News:Plainview Milk Products Cooperative Implements New Employee Boot Policy 2Health News:Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 3Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 4Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 5Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 6Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 7Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 8Health News:New DrainEx(TM) Catheter Simplifies Insertion and Replacement 2
... 1100RS Spectrophotometers are simple, ... for use in many ... educational, clinical, industrial and ... COD vial holders, Windows ...
Spectra 2000 Digital Spectrophotometer is designed for quantitative and qualitative analysis in visible range from 320 nm to 1020 nm....
... Series Spectrophotometer is truly ... UV-VIS instrumentation. The latest ... into a radically new ... and performance unprecedented in ...
... Darkfield Quebec Colony Counter allows the user ... choice of models allows for digital counting or ... over the standard lens increasing magnification to 3.0X. ... lens to be raised or lowered. The lens ...
Medicine Products: